David Lieberman, MD, FACG

David Lieberman, MD, FACG
Professor of Medicine
Division of Gastroenterology, OHSU
Chief of Division OHSU/ VAMC

• Degrees:
  BS — University of Michigan, 1972
  MD — University of Michigan, 1976
  
  
• Residency:
  Internal Medicine - OHSU ,1976-1979
  Chief Resident OHSU, 1979-1980
  
  
• Fellowship:
  Gastroenterology - OHSU,1980-1982
  
  
• Research Interest:
  Outcomes in endoscopy, Colon Cancer Screening, Barrett's esophagus, Gastroesophageal reflux disease, Management of GI Bleeding
  
  
• Clinical Interests:
  Gastroesophageal reflux disease, Barrett's esophagus, colon cancer
  
  
• Representative Publications:
  1. Lieberman DA. Common anorectal disorders. Ann Intern Med. 1984;101:837-46.
  • Lieberman DA, Wuerker CK, Katon RM. Cardiopulmonary risk of endoscopy. Role of endoscopic diameter and type of anesthesia. Gastroenterology. 1985;88:468-72.
  • Lieberman DA, Keeffe EB. Treatment of severe esophagitis with cimetidine and metoclopramide.  Ann Intern Med. 1986;104:21-6.
  • Lieberman DA. Medical therapy of chronic reflux esophagitis: Long-term followup. Arch Intern Med. 1987;147:1717-20.
  • Lieberman DA. 24-hour esophageal pH monitoring before and after medical therapy for reflux esophagitis. Dig Dis Sci.1988;33:166-71.
  • Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol. 1991;86:946-51.
  • Lieberman DA. Cost-effectiveness of colon cancer screening. Am J Gastroenterol. 1991;86:1789-94.
  • Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology. 1995;109:1781-90.
  • Lieberman DA, Sleisenger MH. Is it time to recommend screening for colorectal cancer? The Lancet 1996;348:1463-4.
  • Lieberman DA, Oehlke M, Helfand M and GORGE Consortium. Risk factors for Barrett’s esophagus in community-based practice. Am J Gastroenterol. 1997;92:1293-7.
  • Poorman JC, Lieberman DA, Ippoliti AF, Weber LJ, Weinstein WM. The prevalence of colonic neoplasia in patients with Barrett’s esophagus: A prospective assessment in patients 50 -80 years old. Am J Gastroenterol. 1997;92:592-6.
  • Ellis KK, Oehlke M, Helfand M, Lieberman DA. Management of symptoms of gastroesophageal reflux disease: Does endoscopy influence medical management? Am J Gastroenterol. 1997;92:1472-4.
  • Lieberman DA. National Institutes of Health Workshop on Endoscopic Research Priorities: Introduction; Workshop Statement and recommendations. Gastrointest Endosc. 1999;49:S1-4
  • Lieberman DA, de Garmo PL, Fleischer DE, Eisen GM, Helfand M. Patterns of endoscopy use in the United States. Gastroenterology. 2000;118:619-24.
  • Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H , Chejfec G and Veterans Affairs Cooperative Study Group 380. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000;343:162-8.
  • Lieberman DA, Weiss DG and Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555-60.
  • Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett Esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med. 2003;138:176-86.
  • Lieberman DA, Prindiville S, Weiss DG, Willett W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290:2959-67.
  • Lieberman DA, Fennerty MB, Morris C,  Holub J, Sonnenberg A.  Endoscopic evaluation of patients with dyspepsia: Results from the national endoscopic data repository. Gastroenterology. 2004;127:1067-75.
  • Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: A comparison with recommended sampling practice. Ann Intern Med. 2005;142:81-5.
  • Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, Kikendall JW, Kim HM, Weiss DG, Emory T, Schatzkin A, Lieberman D. Colonoscopic screening of average-risk romen for colorectal neoplasia. N Engl J Med. 2005;352:2061-8.
  • Lieberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Prevalence of polyps greater than 9mm in a consortium of diverse clinical practice settings in the United States. Clin Gastroenterol Hepatol. 2005;3:798-805.
  • Lieberman DA,  Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc. 2005;62:875-83.
  • Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: A consensus update by the US Multi-Society Task Force on colorectal cancer and the American Cancer Society. Gastroenterology. 2006;130:1872-85.
  • Lieberman D. A call to action: Measuring quality of colonoscopy. N Engl J Med. 2006;355:2588-9.
    
    
• Biosketch:
  
  

  Dr. Lieberman has been a member of the OHSU faculty since 1982, and Chief of the GI Division since 1998. He directs several large clinical research studies including:

  • VA Cooperative Study on Colon Cancer Screening 1993-2002
    Funding Source: Veterans Administration
  • Clinical Outcomes Research Initiative ( CORI) 1995-2009
    Funding: American Digestive Health Foundation
    NIH: 1 UO1 DK 57132-01 1999-2004

  Other national activities:

  • Selected for "Best Doctors in America" publication, 1994  
  • Associate Editor of Gastrointestinal Endoscopy 1994-1996
  • Director of NIH Workshop on Endoscopic Research Priorities 12/98
  • President, American Society for Gastrointestinal Endoscopy 2001-2
  • NIH Commission on Digestive Diseases 2006-2008
  • NIH Study Sections: 2002 to present
  • Chair, CDC/American Cancer Society Task force on Colonoscopy
  • Chair Multi-society Task Force on Colorectal Cancer Screening: 2006-present
  • Elected to Association of American Physicians (AAP) - 2006